JPS604421B2 - Absorbent for serum - Google Patents
Absorbent for serumInfo
- Publication number
- JPS604421B2 JPS604421B2 JP52094395A JP9439577A JPS604421B2 JP S604421 B2 JPS604421 B2 JP S604421B2 JP 52094395 A JP52094395 A JP 52094395A JP 9439577 A JP9439577 A JP 9439577A JP S604421 B2 JPS604421 B2 JP S604421B2
- Authority
- JP
- Japan
- Prior art keywords
- serum
- blood cells
- absorbent
- red blood
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Description
【発明の詳細な説明】
本発明は血清に用いる吸収剤に関し、これを詳しくいえ
ば赤血球凝集阻止反応テストにおいて（一般にＨＩテス
トと称する）、人の血清中に含有されているィンヒビタ
ーと抗赤血球因子を、上記ＨＩテストに先立って吸収し
除去するための血清用吸収剤に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an absorbent used for serum, and more specifically, it is used in a hemagglutination inhibition test (generally referred to as HI test) to detect inhibitors and anti-erythrocyte factors contained in human serum. and a serum absorbent for absorbing and removing the above-mentioned HI test.
本発明の吸収剤を、風疹ウイルスの抗体を検査するＨＩ
テストの場合を例にとって説明する。The absorbent of the present invention is used in HI testing for rubella virus antibodies.
This will be explained using a test case as an example.
ウイルス性伝染病の１つである風疹を診断する方法の１
つとして「人の血清中に風疹ウイルスの抗体が生成され
ているかどうかを検査する方法が用いられている。その
方法は、採取した血清中に含まれているィンヒビター（
主としてＰ−リポプロティンといわれている）を除去し
た後、抗赤血球因子を赤血球で吸収し、これを遠心分離
して得た上燈液を希釈用液によって、８倍、１餅音、３
２倍…というように希釈し、その希釈液に風疹ウイルス
の一定量を加え、一定時間例えば１時間放置して抗原一
抗体反応を起こさしめ、次に鳥類例えばニワトリのヒナ
の赤血球（インジケーターとしての赤血球）の一定量を
加え凝集反応の状態を判定し、血清中に含有されている
風疹ウイルスの抗体の有無を検査する。上記の検査にお
いては、上述したように、採取した血清中に含まれてい
るィンヒビターおよび抗赤血球因子を、あらかじめ除去
しておかなければならないのであるが、それには従来の
方法としては、先ずカオリンの適当量を加えて２０分間
放置してカオリンにィンヒビターを吸収せしめ、次いで
インジケーターとして用いられる赤血球と同種の赤血球
の適当量を加え、４℃において約１時間放置して抗赤血
球因子を吸収するという方法が用いられている。Method 1 of diagnosing rubella, a viral infectious disease
One of the methods used is to test whether antibodies against the rubella virus are produced in a person's serum.
After removing the anti-erythrocyte factor (mainly called P-lipoprotein), absorb the anti-erythrocyte factor with red blood cells, centrifuge it, and dilute the supernatant solution with a dilution solution by 8 times, 1 time, 3 times.
Dilute the rubella virus by 2 times, etc., add a certain amount of rubella virus to the diluted solution, leave it for a certain period of time, for example, 1 hour, to cause an antigen-antibody reaction, and then add red blood cells from birds such as chicken chicks (as an indicator). A certain amount of red blood cells) is added to determine the state of agglutination reaction, and the presence or absence of rubella virus antibodies contained in the serum is tested. In the above test, as mentioned above, the inhibitors and anti-erythrocyte factors contained in the collected serum must be removed in advance, but the conventional method for this is to first remove kaolin. A method in which an appropriate amount is added and left for 20 minutes to allow the kaolin to absorb the inhibitor, then an appropriate amount of red blood cells of the same type as the red blood cells used as an indicator is added and left at 4°C for approximately 1 hour to absorb the anti-erythrocyte factor. is used.
本発明者らは鳥類または噸乳動物類の固定赤血球（ホル
ムアルデヒドあるいはグルタルアルデヒドなどで固定し
た赤血球）とカオリンとからなる混合物を用いて錠剤を
調整し、この錠剤を一定量の血清に加えて血清中に分散
せしめることによってきわめて効率的に一段階の操作で
血清中のィンヒビターと抗赤血球因子を吸収し、これを
除去しうろことを発見した。The present inventors prepared tablets using a mixture of fixed red blood cells of birds or mammals (red blood cells fixed with formaldehyde or glutaraldehyde, etc.) and kaolin, and added the tablets to a certain amount of serum. It was discovered that the inhibitors and anti-erythrocyte factors in serum could be absorbed and removed in a very efficient one-step operation by dispersing them in the bloodstream.
本発明はこの発見に基づくものであって、その製法の具
体例を下記に示す。赤血球としては鳥類（例えばニワト
リのヒナ、ガ鳥など）あるいは０甫乳動物類（例えば羊
、人など）の赤血球を用いることができる。上記のよう
な鳥類または０甫乳動物類の血液からセンィ素を除去し
た後、血球を遠心分離し、生理食塩液で数回洗浄した後
、０．２〜２０％のホルムアルデヒドまたはグルタルア
ルデヒド水溶液を用いて固定し、次いで凍結乾燥する。The present invention is based on this discovery, and a specific example of its production method is shown below. As the red blood cells, red blood cells from birds (eg, chicken chicks, moths, etc.) or mammals (eg, sheep, humans, etc.) can be used. After removing the blood cells from the blood of birds or mammals as described above, the blood cells are centrifuged, washed several times with physiological saline, and then treated with a 0.2-20% formaldehyde or glutaraldehyde aqueous solution. and then lyophilized.
この赤血球５０舷多〜１００仏のこ対して、酸洗浄した
カオリン（ｐＨ５．５〜？．５）５０の９を加え、十分
に混合し「 この混合物（５０．０５の９〜５０．１の
９）を成形して１個の錠剤とし、本発明の吸収剤を得る
。本発明の上記吸収剤を用いるには、上記錠剤１個を、
生理食塩液０．３の９を加えた被検血清０．１の‘に加
え、十分に振とうして錠剤を分散せしめた後、室温にお
いて２粉ご間放置し、次いで遠Ｄ操作によって、その上
燈液を採取し、ィンヒビターと抗赤血球因子を吸収、除
去した血清を得、これをＨＩテストに用いる。Add 9 parts of acid-washed kaolin (pH 5.5 to 5) to 50 to 100 red blood cells, mix thoroughly, 9) to form one tablet to obtain the absorbent of the present invention.To use the absorbent of the present invention, one of the tablets is
Add 0.1 part of the test serum to 0.3 parts of physiological saline solution, shake thoroughly to disperse the tablets, leave the tablets at room temperature, and then use a far-D operation. In addition, the kerosene solution is collected, and serum from which inhibitors and anti-erythrocyte factors have been absorbed and removed is obtained, which is used for the HI test.
Claims (1)
て固定した、鳥類または哺乳動物類の赤血球と、カオリ
ンの混合物からなる血清用吸収剤において、上記混合物
の一定量を加圧成形して錠剤の形にしたことを特徴とす
る血清用吸収剤。1. A serum absorbent consisting of a mixture of avian or mammalian red blood cells fixed with formaldehyde or glutaraldehyde and kaolin, characterized in that a certain amount of the mixture is press-molded into a tablet shape. Absorbent for serum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP52094395A JPS604421B2 (en) | 1977-08-06 | 1977-08-06 | Absorbent for serum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP52094395A JPS604421B2 (en) | 1977-08-06 | 1977-08-06 | Absorbent for serum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5428814A JPS5428814A (en) | 1979-03-03 |
| JPS604421B2 true JPS604421B2 (en) | 1985-02-04 |
Family
ID=14109071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52094395A Expired JPS604421B2 (en) | 1977-08-06 | 1977-08-06 | Absorbent for serum |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS604421B2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2036309B (en) * | 1978-02-06 | 1982-10-06 | Takeda Chemical Industries Ltd | Viral hemoagglutination inhibition test |
| JPS57208459A (en) * | 1981-06-19 | 1982-12-21 | Eisai Co Ltd | Measuring method using enzyme-labelled antibody and reagent |
| JPS5877547A (en) * | 1981-10-30 | 1983-05-10 | Inoue Japax Res Inc | Colored metal |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52154518A (en) * | 1976-06-15 | 1977-12-22 | Uerumaa Japan Yuugen | Production of serum treating agent for virus nonspecific reaction |
-
1977
- 1977-08-06 JP JP52094395A patent/JPS604421B2/en not_active Expired
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52154518A (en) * | 1976-06-15 | 1977-12-22 | Uerumaa Japan Yuugen | Production of serum treating agent for virus nonspecific reaction |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5428814A (en) | 1979-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Michalak | Immune complexes of hepatitis B surface antigen in the pathogenesis of periarteritis nodosa. A study of seven necropsy cases. | |
| Halstead | Immunological parameters of togavirus disease syndromes | |
| Stanley | Isolation of a crystalline protein possessing the properties of tobacco-mosaic virus | |
| Scott et al. | A simple modification of the Middlebrook and Dubos hemagglutination test for serum antibodies to products of tubercle bacilli | |
| Hänninen et al. | Involvement of the central nervous system in acute, uncomplicated measles virus infection | |
| Webster et al. | An inhibition test for identifying the neuraminidase antigen on influenza viruses | |
| Boyle et al. | Electron microscopic identification of virus-like particles in laryngeal papilloma | |
| Pruzansky et al. | Histamine release from leukocytes of hypersensitive individuals: I. Use of several antigens | |
| Lou et al. | Experimental infections with Coxsackie viruses: II. Myocarditis in cynomolgus monkeys infected with B4 virus | |
| Leahey et al. | Combined mexiletine and propranolol treatment of refractory ventricular tachycardia. | |
| JPS604421B2 (en) | Absorbent for serum | |
| Eaton et al. | Complement-Fixation in Human Pneumonitis with Group-Reactive Virus Antigens. | |
| Arbesman et al. | Allergenic potency of bee antigens measured by RAST inhibition | |
| Schwartz et al. | Studies in stinging insect hypersensitivity: postmortem demonstration of antivenom IgE antibody in possible sting-related sudden death | |
| US4140754A (en) | Hemagglutination-inhibition test for togaviruses | |
| Labzoffsky et al. | Studies on the antigenic structure of Trichinella spiralis larvae | |
| Elwasife et al. | Effects of noise on rabbit’s blood | |
| Snoeyenbos et al. | Further studies of virus hepatitis of turkeys | |
| Lammers et al. | Unsuccessful attempt to demonstrate a paralytic factor in serum of myasthenia gravis patients | |
| SU1665268A1 (en) | Method for thromboembolism diagnosis | |
| Jaeger‐Draafsel et al. | Detection of incomplete platelet antibodies by means of the indirect anti‐human globulin test | |
| SU715088A1 (en) | Method of obtaining erythrocytic diagnosticum | |
| Lafrado et al. | Polymorphonuclear leukocyte function in HIV-1-infected chimpanzees | |
| US4335096A (en) | Absorbent for use in passive agglutination test | |
| JPS5630648A (en) | Latex sensitized with echo virus antigen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees | ||
| S199 | Written request for registration of transfer of right |
Free format text: JAPANESE INTERMEDIATE CODE: R313199 |
|
| R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |